Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug safety checked in Long-Term study

NCT ID NCT04164199

Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety of several cancer drugs, including tislelizumab and pamiparib, in 404 people with advanced cancers. Participants had already been in an earlier trial of these drugs. The goal was to track serious side effects and see if patients could keep benefiting from treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

404 people

The number who actually took part.

Started

Dec 2019

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Currently participating in a BeiGene- or BeOne-sponsored eligible parent study 2. Fulfills treatment criteria specified in the parent study protocol 3. In the opinion of the investigator, the participant will continue to benefit from and tolerate any of the parent study treatments. 4. The first dose of study treatment in the LTE study will be received within the treatment interruption period allowed by the parent study: 1. "Treatment interruption" is an unplanned pause in study treatment (eg, due to adverse event). Restarting study treatment beyond the interruption period allowed by the parent study will be determined by the investigator and the sponsor. Key Exclusion Criteria: 1. Permanently discontinued from all investigational drugs in the parent study due to unacceptable toxicity, noncompliance with study procedures, or withdrawal of consent 2. Have uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy prior to the start of the extension study 3. Have a medical condition or organ system dysfunction that in the investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of investigational drugs, or put the study outcomes at undue risk 4. Underwent treatment with any systemic anticancer treatment (other than treatment permitted in the parent study) during the time between the last treatment in the parent study and the first dose of study treatment in the LTE study 5. Pregnant or lactating women NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced malignancies

Contacts and locations

Locations

  • Acibadem Adana Hospital

    Kuruköprü, 01060, Turkey (Türkiye)

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guangzhou, Guangdong, 510030, China

  • Affiliated Cancer Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, 830000, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, 071000, China

  • Affiliated Zhongshan Hospital of Fudan University

    Shanghai, Shanghai Municipality, 200032, China

  • Ajou University Hospital

    Suwon, 16499, South Korea

  • Akita University Hospital

    Akitashi, Akita, 010-8543, Japan

  • Aou Pisana, Stabilimento Di Santa Chiara

    Pisa, 56126, Italy

  • Asan Medical Center

    SongpaGu, Seoul Teugbyeolsi, 05505, South Korea

  • Auckland City Hospital

    Auckland, 1023, New Zealand

  • Azienda Ospedaliera S Maria Di Terni

    Terni, 05100, Italy

  • Bakirkoy Sadi Konuk Eah

    stanbulBakrkoy, 34147, Turkey (Türkiye)

  • Baylor Research Institute

    Dallas, Texas, 75246-2079, United States

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Calvary Mater Newcastle

    Waratah, New South Wales, NSW 2298, Australia

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100021, China

  • Centre Hospitalier Universitaire Nantes Hotel Dieu

    Nantes, 44000, France

  • Cha Bundang Medical Center, Cha University

    BundangGu SeongnamSi, Gyeonggi-do, 13496, South Korea

  • Chi Mei Medical Center

    Yongkang Dist, 710, Taiwan

  • Chiayi Chang Gung Memorial Hospital

    Chiayi City, 61363, Taiwan

  • Chiba Cancer Center

    Chiba, Chiba, 260-8717, Japan

  • China Medical University Hospital

    Taichung, 40447, Taiwan

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, 400030, China

  • Chonnam National University Hwasun Hospital

    HwasunGun, Jeollanam-do, 58128, South Korea

  • First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, 116011, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200000, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350014, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, 350001, China

  • Gachon University Gil Medical Center

    NamdongGu, Incheon Gwang'yeogsi, 21565, South Korea

  • Guangdong Provincial Peoples Hospital

    Guangzhou, Guangdong, 510080, China

  • Hainan Cancer Hospital

    Haikou, Hainan, 570312, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, 150000, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Hokkaido University Hospital

    Sapporo, Hokkaido, 060-8648, Japan

  • Hopital Beaujon

    Clichy, 92110, France

  • Hopital Larchet 2 Chu Nice

    Nice, 06200, France

  • Hopital Prive Jean Mermoz

    Lyon, 69008, France

  • Hubei Cancer Hospital

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Icm Val Daurelle

    Montpellier, 34090, France

  • Icon Cancer Centre South Brisbane

    South Brisbane, Queensland, QLD 4101, Australia

  • Institute of Hematology and Hospital of Blood Disease

    Tianjin, Tianjin Municipality, 300020, China

  • Izumi City General Hospital

    Izumishi, Osaka, 594-0073, Japan

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China

  • Jilin Cancer Hospital

    Changchun, Jilin, 130021, China

  • Kaohsiung Chang Gung Memorial Hospital

    Niaosong Dist, 83301, Taiwan

  • King Chulalongkorn Memorial Hospital (Chulalongkorn University)

    Pathum Wan, 10330, Thailand

  • Korea University Guro Hospital

    GuroGu, Seoul Teugbyeolsi, 08308, South Korea

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, 110042, China

  • Linkou Chang Gung Memorial Hospital

    Guishan Dist, 33305, Taiwan

  • Memorial Sloan Kettering Cancer Center Mskcc

    New York, New York, 10065-6800, United States

  • Monash Health

    Clayton, Victoria, VIC 3168, Australia

  • Mount Sinai Medical Center Braman Comprehensive Cancer Center

    Miami, Florida, 33140, United States

  • Namik Kemal University

    Tekirdağ, 59100, Turkey (Türkiye)

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510515, China

  • Narodowy Instytut Onkologii Im Marii Sklodowskiej Curie W Warszawie

    Warsaw, 02-781, Poland

  • National Cancer Center (Korea)

    IlsandongGu GoyangSi, Gyeonggi-do, 10408, South Korea

  • National Cancer Center Hospital

    ChuoKu, Tokyo, 104-0045, Japan

  • National Cheng Kung University Hospital

    North Dist, 704, Taiwan

  • Nho Kyushu Cancer Center

    Fukuoka, Fukuoka, 811-1395, Japan

  • Northern Cancer Institute

    St Leonards, New South Wales, NSW 2065, Australia

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, VIC 3000, Australia

  • Policlinico Sorsola Malpighi, Aou Di Bologna

    Bologna, 40138, Italy

  • Prince of Wales Hospital

    Randwick, New South Wales, NSW 2031, Australia

  • Samsung Medical Center

    GangnamGu, Seoul Teugbyeolsi, 06351, South Korea

  • Sarawak General Hospital

    Kuching, 93586, Malaysia

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Severance Hospital Yonsei University Health System

    SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea

  • Shandong Cancer Hospital

    Jinan, Shandong, 250117, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, 200030, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310016, China

  • Smg Snu Boramae Medical Center

    DongjakGu, Seoul Teugbyeolsi, 07061, South Korea

  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North)

    Guangzhou, Guangdong, 510000, China

  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)

    Guangzhou, Guangdong, 510245, China

  • Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia

    Gdynia, 81-519, Poland

  • Taichung Veterans General Hospital

    Taichung, 407, Taiwan

  • Tennessee Oncology, Pllc Nashville

    Nashville, Tennessee, 37203, United States

  • The Affiliated Hospital of Military Medical Sciences

    Beijing, Beijing Municipality, 100071, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, 221000, China

  • The Catholic University of Korea, Seoul St Marys Hospital

    SeochoGu, Seoul Teugbyeolsi, 06591, South Korea

  • The Catholic University of Korea, St Vincents Hospital

    PaldalGu SuwonSi, Gyeonggi-do, 16247, South Korea

  • The Fifth Affiliated Hospital Sun Yat Sen University

    Zhuhai, Guangdong, 519000, China

  • The First Affiliated Hospital of Nanchang University Branch Donghu

    Nanchang, Jiangxi, 330006, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, 361003, China

  • The First Affiliated Hospital of Xian Jiaotong University

    Xi'an, Shaanxi, 710061, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450052, China

  • The First Hospital of Jilin University

    Changchun, Jilin, 130021, China

  • The First Peoples Hospital of Changzhou

    Changzhou, Jiangsu, 213000, China

  • The First Provincial Wenzhou Hospital of Zhejiang

    Wenzhou, Zhejiang, 325000, China

  • The Peoples Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, 530021, China

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, SA 5011, Australia

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310009, China

  • The Second Affiliated Hospital of Zunyi Medical University

    Zuiyi, Guizhou, 550002, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, 230601, China

  • The University of Osaka Hospital

    Suitashi, Osaka, 565-0871, Japan

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, 300060, China

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

  • University Malaya Medical Centre

    Kuala Lumpur, 59100, Malaysia

  • Weifang Peoples Hospital

    Weifang, Shandong, 261000, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

  • West China Second University Hospital, Sichuan University

    Chengdu, Sichuan, 610101, China

  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200092, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

  • Zhongnan Hospital of Wuhan University Wuhan

    Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.